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appeared sufficient for BAM. The slightly inferior results on 
target coverage for MSM are likely due to the variations of 
the femoral head positions influencing proton range and dose 
distribution. 
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Purpose/Objective: Patients with head and neck cancer can 
experience considerable tumour shrinkage during their 
treatment course which in turn can lead to alterations of the 
planned dose distribution. In this study we evaluate and 
compare the robustness of standard and dose-painted plans 
in presence of extensive tumour shrinkage. 
Materials and Methods: Eleven patients with extensive in-
treatment tumour shrinkage (mean shrinkage 87.2 cm^3) 
were selected for this retrospective study. The patients 
underwent 3 to 5 CT scans during their course of 
radiotherapy (RT). Two planning strategies were simulated on 
this dataset using VMAT: 1) standard integrated boost plans 
delivering a uniform dose of 2 Gy x 34 to the tumor PTV and 
2) a data-driven dose-painting protocol (CONTRAST), in which 
five different dose levels are given, with the 18F-
fludeoxyglucose PET-positive region receiving 2.35 Gy x 34.  
An expert radiation oncologist manually contoured the GTV 
on all in-treatment scans, to which the plans were then 
transferred and recalculated. The GTV volume as well as the 
dose to the spinal cord and the mandible were reported. 
Using the Wilcoxon matched pairs signed rank test we tested 
the hypothesis that tumour shrinkage causes significant dose 
increase to the spinal cord and the mandible. Finally we 
investigated if there was any significant difference in dose 
increase to these OAR's between the standard protocol and 
the CONTRAST protocol. 
Results: A significant in-treatment dose-increase was found 
in the spinal cord (p < 0.003) of 1.1 Gy +/-0.9 Gy (median +/- 
interquartile range) using the standard protocol and 1.2 Gy 
+/- 1.6 Gy using the CONTRAST protocol (illustrated in figure 
1, bottom). The increase in spinal cord dose was not 
statistically different between the two planning strategies 
(P=0.77). 
In the mandible a dose increase of 0.5 Gy +/- 0.8 Gy using 
standard plans and 1.35 Gy +/- 1.6 Gy using CONTRAST-plans 
was found. For patients with a PET-positive volume close to 
the mandible, the dose constraint to this OAR was clearly 




Conclusions: Tumour shrinkage had a statistically significant 
impact on the delivered doses to the spinal cord and the 
mandible. The dose increase found is modest in both organs 
in spite of considerable tumour shrinkage. Standard plans and 
dose-painted plans created using the CONTRAST protocol are 
equally robust with regard to the spinal cord and the increase 
in dose is probably clinically irrelevant. Standard plans 
appear more robust than CONTRAST plans with regard to the 
mandible, due to high dose boosting of regions close to the 
OAR (see figure 1). For cases where large tumours are in 
proximity of an important OAR and a large tumour shrinkage 
is observed, an adaptive strategy may be necessary. 
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Purpose/Objective: To use cone beam computed tomography 
(CBCT) images for reliable and robust proton dose and range 
calculations. Scatter induced reconstruction errors are the 
dominant artifacts affecting CBCT HU accuracy. In order to 
generate a CBCT image for reliable dose and range 
calculations, scatter effects must be removed. 
Materials and Methods: Two common scatter correction 
methods were tested: uniform scatter model and a priori CT 
based scatter generation. Images were acquired for a 
electron density calibration phantom, multiple 
anthropomorphic phantoms, and patients selected from 
multiple treatment locations including cranial, prostate, and 
thoracic. For the phantom studies the diagnostic CT was 
considered to be the gold standard for dose and range 
calculations. For the patient studies, all daily comparisons 
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are to the first daily CBCT and the planning CT. Water 
equivalent path lengths and doses to the PTVs using a 3D 
gamma analysis were analyzed. Additional phantom 
experiments were conducted to evaluate mild deformations 
simulating weight gain/loss and rectal filling/draining. 
Results: For the phantom tests, uncorrected CBCT 
reconstructions had the largest HU value differences 
compared to the reference CT while the a priori scatter 
corrected CBCT reconstruction had the most accurate HU 
values. Regarding WEPL, the uncorrected CBCT had average 
of errors of 5-13 mm depending upon the phantom size and 
herterogeneities. A uniform scatter corrected CBCT had 
average range error of 3-22 mm and the a priori scatter 
corrected CBCT had average range errors of 1-3 mm (See 
Table). All WEPL errors were calculated using the refence CT 
of the phantoms. Doses were calculated in the same 
phantoms using targets simulating realistic clinical scenarios 
and beam combinations routinely used in the clinic. Gamma 
pass rates for 2%/2mm and 3%/3mm were always highest for 
the a priori scatter corrected CBCT at 96% and 99%, 
respectively. For uniform corrected CBCT dose calculations, 
the gamma pass rates were 78% (2%/2mm) and 86% (3%/3mm) 
with the worst cases being in the thorax due to an 
overestimation of the uniform scatter model with less 
attenuation and scatter in the lung. Patient doses were 
calculated with similar gamma pass rates but gamma rates 
varied more due to the realistic presence of patient daily 
variations of shape, target position and deformation of 
internal anatomy (see Figure for Prostate Example).  
 
 
Conclusions: Daily CBCT can be used for daily proton dose 
and range calculations for adaptive proton therapy when 
using an a priori scatter correction method. WEPL errors have 
been reduced from 13 mm to 3 mm and dose calculations can 
be performed with gamma 2%/2mm errors of less than 4%. 
Deformations due to weight gain/loss and target motion can 
be assessed with the proposed reconstruction methods. 
Further refinements in the CBCT reconstruction accounting 
for beam hardening and HU calibration specificity can reduce 
the range error below 3 mm.  
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Purpose/Objective: A concern with the use of VMAT in 
hypofractionated lung treatments is whether tumour motion 
will lead to significant discrepancies between calculated and 
planned dose distributions. Our study aimed at: 
a) Evaluating whether planning on the average CT scan (AVG 
CT) allows for a good representation of the dose distribution 
delivered to the moving target when 'interplay' is not 
considered; 
b) Quantifying the interplay effect between tumour motion 
and dose delivery using a moving phantom and GafChromic 
EBT3 films. 
Materials and Methods: 
Patients 
For ten patients who received lung treatment (54 Gy in 3 
fractions), VMAT plans generated with Monaco TPS on the 
AVG CT were recalculated on each phase of the 4DCT and the 
resulting plans were compared. A Philips BigBore CT scanner 
was used to acquire and reconstruct images (retrospective 
method based on phase detection). All patients had an ITV 
defined using the maximum intensity projection (MIP). A PTV 
was created as a 5 mm isotropic expansion of the ITV.  
Phantom 
A motor driven moving phantom was customized with an add-
on device consisting of a circular 3 cm diameter tissue 
equivalent sphere in polystyrene. The phantom moves in the 
cranio-caudal direction (2 cm peak-to-peak), with a 
frequency of 15 cycles/min and with an 'inspiration' phase 
shorter than the 'expiration' phase. EBT3 films can be 
inserted in the sphere simulating the target. 
Plans were generated on the AVG CT in two different ways: 
1) with no density override and 2) setting the ITV density to 
the mean GTV density and the PTV-ITV shell to an 
intermediate density between lung and GTV. The density 
override was performed with the further aim of reducing the 
dose distribution modulation that is induced by the 
difference in density between ITV and PTV-ITV, but which is 
neither intentional nor desired. 
In order to single out the interplay effect, plans were also 
generated optimizing and prescribing to the ITV only (both 
with and without density override). 




In Table the results of the patient plan are reported, showing 
moderate variations between the AVG CT plan and the plans 
recalculated on each phase of the 4DCT. None of the 
parameters shows any statistically significant correlation 
between the variation and the extent of tumour 
displacement. 
